A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failu
A phase 3 trial of Tabelecleucel run by Pierre Fabre Medicament, now recruiting.
Overview
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy is a phase 3 interventional study registered as NCT03394365 by Pierre Fabre Medicament, with 115 participants planned, started 2017-12-29. Conditions listed: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant. No results are recorded here; the registry entry is the source.
Setting
Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy
Phase
Phase 3
Sponsor
Pierre Fabre Medicament
Registry
Enrolled
115